Cite
HARVARD Citation
Blinman, P. et al. (2018). Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?. Annals of oncology. pp. 370-376. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Blinman, P. et al. (2018). Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?. Annals of oncology. pp. 370-376. [Online].